Jonathan S. Berek
Publications
- Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. J Clin Oncol. 2013; (12): 1554-61
- Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study. Obstet Gynecol. 2013; (4): 709-716
- Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2012: S118-29
- Current management of vulvar cancer. Hematol Oncol Clin North Am. 2012; (1): 45-62
- FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. Nat Commun. 2012: 1000
- Personalizing CA125 levels for ovarian cancer screening. Cancer Prev Res (Phila). 2011; (9): 1356-9
- Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy: Recommendations Based on Risk of Ovarian Cancer. Obstet Gynecol. 2011; (2 Pt 1): 404
- Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol. 2010; (3): 733-43
- Strategies and goals: the future of the International Gynecologic Cancer Society: IGCS Presidential Address. Int J Gynecol Cancer. 2010; (9): 1434-9
- Lymph node-positive stage IIIC ovarian cancer: a separate entity? Int J Gynecol Cancer. 2009: S18-20
- Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009; (3): 418-25
- Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol. 2009; (5): 1027-37
- Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience. Int J Gynecol Cancer. 2009; (2): 223-9
- CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother. 2008 Feb-Mar; (2): 207-14
- HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review. Gynecol Oncol. 2008; (3): 568-71
- Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol. 2008; (3): 652-7
- Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. Am J Obstet Gynecol. 2008; (2): 216.e1-5
- Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008; (2): 218.e1-6
- Elective oophorectomy for benign gynecological disorders. Menopause. 2007 May-Jun; (3 Pt 2): 580-5
- Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol. 2007; (1): 12-9
- CA125: megadaltons of novel opportunities. Gynecol Oncol. 2007; (3): 505-7
- Elective oophorectomy in the gynecological patient: when is it desirable? Curr Opin Obstet Gynecol. 2007; (4): 350-4
- Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol. 2007; (20): 2975-82
- Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol. 2007; (6): 1342-50
- Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Cancer. 2007; (12): 2454-60
- Ovarian conservation at the time of hysterectomy for benign disease. Clin Obstet Gynecol. 2007; (2): 354-61
- Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007; (3): 655-62
- Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women. Gynecol Oncol. 2007; (2): 396-400
- The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer. 2007; (12): 1817-22
- Vulvar melanoma: a multivariable analysis of 644 patients. Obstet Gynecol. 2007; (2 Pt 1): 296-301
- Progress in ovarian cancer research: proceedings of the 5th Biennial Ovarian Cancer Research Symposium. Int J Gynecol Cancer. 2006 Mar-Apr; (2): 463-9
- An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Int J Gynecol Cancer. 2006 Jan-Feb; (1): 125-34
- 10th Biennial Helene Harris Memorial Trust meeting. Cancer Res. 2006; (6): 2904-6
- Intraperitoneal chemotherapy for ovarian cancer. Curr Opin Oncol. 2006; (5): 507-15
- Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006; (10): 1314-20
- Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006; (3 Pt 1): 521-8
- Response to commentaries on retention of the ovaries and long-term survival after hysterectomy. Climacteric. 2006; (5): 396-8; author reply 398-400
- Surgery for ovarian cancer: how to improve survival. Lancet. 2006; (9522): 1558-60
- The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecol Oncol. 2006; (3): 1095-9
- Design, conduct and evaluation of a communication course for oncology fellows. J Cancer Educ. 2005; (3): 143-9
- Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005; (1): 108-11
- Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies. Gynecol Oncol. 2005; (2): 685-92
- Monoclonal antibody therapy of ovarian cancer. Expert Rev Anticancer Ther. 2005; (1): 87-96
- Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol. 2005; (1): 153-9
- Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol. 2005; (3): 721-8
- Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. Clin Cancer Res. 2004; (8): 2681-6
- Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther. 2004; (7): 1159-65
- Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol. 2004; (17): 3507-16
- Using fresh tissue dissection to teach human anatomy in the clinical years. Acad Med. 2004; (7): 711-6
- Cervical cancer: an opportunity to prevent and cure. Cancer J. 2003 Sep-Oct; (5): 325-6
- Surgical resection of solitary brain metastasis from cervical cancer. Int J Gynecol Cancer. 2003 May-Jun; (3): 368-70
- CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2003 Mar-Apr; (2): 120-4
- The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. Int J Gynecol Cancer. 2003 Mar-Apr; (2): 138-41
- Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. Gynecol Oncol. 2003; (2): 325-30
- Biologic and immunologic therapies for ovarian cancer. J Clin Oncol. 2003; (10 Suppl): 168s-174s
- Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. Eur J Cancer. 2003; (13): 1818-27
- Lymphovascular and perineural invasion in the parametria: a prognostic factor for early-stage cervical cancer. Obstet Gynecol. 2003; (3): 612-9
- Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2003; (1): 177-80
- Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol. 2003; (10 Suppl): 129s-132s
- Simplification of the new Bethesda 2001 classification system. Am J Obstet Gynecol. 2003; (3 Suppl): S2-5; discussion S6-7
- Specific keynote: immunological therapy for ovarian cancer. Gynecol Oncol. 2003; (1 Pt 2): S105-9; discussion S110-3
- FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int J Gynecol Cancer. 2002 Sep-Oct; (5): 454-8
- Advances in the management of epithelial ovarian cancer. J Reprod Med. 2001; (7): 621-9; discussion 629-30
- Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000 Jul-Aug; (1): 3-10
- [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. Gynecol Obstet Fertil. 2000 Jul-Aug; (7-8): 576-83
- A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: a case report and review of the literature. J Am Coll Surg. 2000; (2): 212-5
- Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000; (8): 1606-13
- Fraud. What is the evidence? Care Manag J. 2000; (1): 44-53
- Interferon plus chemotherapy for primary treatment of ovarian cancer. Lancet. 2000; (9223): 6-7
- Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125. Gynecol Oncol. 2000; (2): 225-6
- Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol. 1999: 87-92
- Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future? Ann Oncol. 1999: 69-73
- Endometrial cancer: recent developments in evaluation and treatment. Oncology (Williston Park). 1999; (12): 1665-70; discussion 1675-8, 1681-2
- IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. J Immunol. 1999; (12): 6378-85
- Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study. Gynecol Oncol. 1999; (1): 48-52
- Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study. Gynecol Oncol. 1999; (1): 10-4
- Recurrent mature cystic teratoma presenting as a perihepatic mass. Obstet Gynecol. 1999; (5 Pt 2): 856
- Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol. 1999: 3-7
- A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 1998; (3): 410-5
- Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. Gynecol Oncol. 1998; (2): 204-10
- Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer. Cancer Treat Res. 1998: 253-76
- Progress in ovarian cancer. Curr Opin Obstet Gynecol. 1998; (1): 51-5
- Psammocarcinoma with an aggressive course. Obstet Gynecol. 1998; (4 Pt 2): 659-61
- Reducing loss-to-follow-up among women with abnormal Pap smears. Results from a randomized trial testing an intensive follow-up protocol and economic incentives. Med Care. 1998; (3): 397-410
- Gene therapy for ovarian cancer: development of novel treatment strategies. Int J Gynecol Cancer. 1997; (1): 1-13
- Complete debulking of epithelial ovarian cancer. Cancer J Sci Am. 1996 May-Jun; (3): 132-3
- Dysgerminoma: the role of conservative surgery. Gynecol Oncol. 1996; (3): 352-7
- Evidence for a unifocal origin in familial ovarian cancer. Am J Obstet Gynecol. 1996; (4): 1102-6; discussion 1106-8
- Mixed mesodermal sarcoma of the ovary in a young patient. Eur J Obstet Gynecol Reprod Biol. 1996; (2): 249-53
- Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma. Gynecol Oncol. 1996; (1): 97-100
- Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995; (7): 1589-99
- Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer, May 4-7, 1995, Glasgow, UK. Int J Gynecol Cancer. 1995; (6): 449-458
- Interval debulking of ovarian cancer--an interim measure. N Engl J Med. 1995; (10): 675-7
- Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial. Gynecol Oncol. 1995; (2): 164-8
- Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer. 1995; (10 Suppl): 2092-6
- Ovarian cancer spread: is laparoscopy to blame? Lancet. 1995; (8969): 200
- Radiation therapy for adenocarcinoma of the uterine cervix: does the histology matter? Int J Radiat Oncol Biol Phys. 1995; (5): 1543-4
- Surgical management of ovarian cancer. Semin Surg Oncol. 1994 Jul-Aug; (4): 268-75
- A multicenter study of laparoscopic management of selected cystic adnexal masses in postmenopausal women. J Am Coll Surg. 1994; (6): 733-7
- Advances in the biology of gynecologic cancer. Curr Opin Oncol. 1994; (5): 513-8
- Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2N0-1M0) disease. Gynecol Oncol. 1994; (1): 55-8
- Cytokine-induced modulation of tumor suppressor gene expression in ovarian cancer cells: up-regulation of p53 gene expression and induction of apoptosis by tumor necrosis factor-alpha. Am J Obstet Gynecol. 1994; (4): 1121-8; discussion 1128-30
- Fine-needle aspiration cytology in the management of gynecologic oncology patients. Cancer Treat Res. 1994: 1-13
- Laparoscopic management of the adnexal mass. Obstet Gynecol Clin North Am. 1994; (1): 79-92
- Management of Selected Adnexal Masses in Postmenopausal Women by Operative Laparoscopy-A Multicentered Study J Am Assoc Gynecol Laparosc. 1994; (4, Part 2): S27
- Molecular and biologic factors in the pathogenesis of ovarian cancer. J Reprod Med. 1994; (4): 241-8
- Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes. Obstet Gynecol. 1994; (4 Pt 2): 724-6
- Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal carcinomatosis. Int J Gynecol Cancer. 1994; (1): 43-51
- Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol. 1994; (5): 897
- Salvage therapy for recurrent and refractory ovarian cancer with high-dose chemotherapy and autologous bone marrow support: a Gynecologic Oncology Group pilot study. Gynecol Oncol. 1994; (2): 142-6
- The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994; (4): 974-9; discussion 979-80
- The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol. 1994; (1): 108-10
- Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol. 1994; (3): 414-8
- Advanced epithelial ovarian cancer: 1993 consensus statements. Ann Oncol. 1993: 83-8
- Advanced ovarian cancer. Tumour markers. Ann Oncol. 1993: 71-7
- Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res. 1993; (2): 332-9
- Current management of invasive squamous carcinoma of the vulva. Clin Geriatr Med. 1993; (1): 131-43
- Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol. 1993; (1): 8-15
- Impact of contraception on gynecologic cancers. Am J Obstet Gynecol. 1993; (6 Pt 2): 1980-5
- Molecular and biological factors in the pathogenesis of ovarian cancer. Ann Oncol. 1993: 3-16
- Primary leiomyosarcoma of the ovary in a perimenarchal female. Gynecol Oncol. 1993; (3): 389-93
- Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study) Gynecol Oncol. 1993; (3): 279-83
- Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype. Gynecol Oncol. 1993; (2): 214-20
- Solitary recurrent metastasis of epithelial ovarian cancer in the spleen. Gynecol Oncol. 1993; (3): 338-41
- Biologic and immunologic therapy of ovarian cancer. Hematol Oncol Clin North Am. 1992; (4): 941-65
- Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon. Gynecol Oncol. 1992; (1): 3-8
- Early-stage squamous cell and adenocarcinoma of the cervix. Curr Opin Obstet Gynecol. 1992; (1): 109-19
- Improving adherence to screening follow-up among women with abnormal Pap smears: results from a large clinic-based trial of three intervention strategies. Med Care. 1992; (3): 216-30
- Intraperitoneal immunotherapy for ovarian cancer with alpha interferon. Eur J Cancer. 1992; (4-5): 719-21
- Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine. 1992; (5): 385-90
- Second-look versus second-nature. Gynecol Oncol. 1992; (1): 1-2
- Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. Am J Obstet Gynecol. 1992; (3): 997-1007
- Interleukin 6 and cancer treatment. In Vivo. 1991 Nov-Dec; (6): 583-8
- A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer. Gynecol Oncol. 1991; (3): 237-43
- Adnexal torsion. An unusual cause of abdominal pain in postmenopausal women. Am Surg. 1991; (5): 327-9
- Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol. 1991; (4): 997-1003; discussion 1003-4
- Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Gynecol Oncol. 1991; (3): 197-201
- Fine-needle aspiration cytology accuracy with palpable gynecologic neoplasms. Gynecol Oncol. 1991; (1): 70-3
- Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991; (4): 1038-42; discussion 1042-3
- Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers. Anticancer Res. 1990 Mar-Apr; (2A): 441-6
- Adjuvant therapy for early-stage ovarian cancer. N Engl J Med. 1990; (15): 1076-8
- Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 1990; (21): 6959-65
- Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells. Cancer Chemother Pharmacol. 1990; (1): 1-8
- Cytoreductive surgery for advanced ovarian cancer: cardiovascular evaluation with pulmonary artery catheters. Gynecol Oncol. 1990; (3): 311-4
- Intraperitoneal adoptive immunotherapy for peritoneal cancer. J Clin Oncol. 1990; (10): 1610-2
- Malignant neoplasms arising in endometriosis. Obstet Gynecol. 1990; (6): 1023-8
- Management of selected cystic adnexal masses in postmenopausal women by operative laparoscopy: a pilot study. Am J Obstet Gynecol. 1990; (5 Pt 1): 1574-7
- Ovarian metastases are rare in stage I adenocarcinoma of the cervix. Obstet Gynecol. 1990; (4): 623-6
- Pathophysiology and management of endometrial hyperplasia and carcinoma. West J Med. 1990; (1): 50-61
- Pelvic hemangiopericytomas: a report of five cases and literature review. Gynecol Oncol. 1990; (3): 380-2
- Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group study. Invest New Drugs. 1990; (2): 191-4
- Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. Cancer Res. 1990; (22): 7364-70
- Risk factors for the development of lymph node metastasis in vulvar squamous cell carcinoma. Gynecol Oncol. 1990; (1): 9-16
- Surgical staging of cervical cancer. Clin Obstet Gynecol. 1990; (4): 852-62
- Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol. 1990; (3): 309-14
- Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells. Gynecol Oncol. 1990; (3): 333-9
- Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells. Cancer. 1989; (2): 434-41
- Human neutrophil-mediated lysis of ovarian cancer cells. Blood. 1989; (2): 805-9
- Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients. Obstet Gynecol. 1989; (5 Pt 1): 793-7
- Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1989; (4): 457-65
- Resection of diaphragmatic peritoneum and muscle: role in cytoreductive surgery for ovarian cancer. Gynecol Oncol. 1989; (3): 338-40
- Screening, diagnosis, and monitoring of gynecologic malignancies. Curr Opin Oncol. 1989; (1): 75-81
- Synchronous primary neoplasms of the female reproductive tract. Gynecol Oncol. 1989; (3): 335-9
- Synergistic effect of combined intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model. Obstet Gynecol. 1989; (4): 663-6
- Utilization of a murine model to optimize volume and dwell time of intraperitoneal cisplatin. Gynecol Oncol. 1989; (1): 66-9
- Vulvovaginal melanoma: report of seven cases and literature review. Gynecol Oncol. 1989; (1): 54-60
- Uterine corpus and cervical cancer. Curr Probl Cancer. 1988 Mar-Apr; (2): 61-131
- Controversies in the management of cervical adenocarcinoma. Obstet Gynecol. 1988; (2): 261-9
- Immunologic control of ovarian cancer. Nat Immun Cell Growth Regul. 1988; (4): 216-25
- Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity. Cancer Res. 1988; (20): 5853-9
- Minimal cervical cancer: definition and histology. Recent Results Cancer Res. 1988: 47-56
- Peritoneal cytology of ovarian cancer patients receiving intraperitoneal therapy: quantitation of malignant cells and response. Obstet Gynecol. 1988; (5): 782-8
- Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol. 1988; (2): 341-6
- Sensitivity of fresh and cultured ovarian tumor cells to tumor necrosis factor, interferon-alpha 2, and OK-432. Cancer Immunol Immunother. 1988; (3): 246-54
- CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol. 1987; (2): 223-7
- Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervix. Appl Pathol. 1987; (1): 47-56
- Distant metastases in epithelial ovarian carcinoma. Cancer. 1987; (7): 1561-6
- Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarian cancer. Obstet Gynecol. 1987; (5): 759-64
- Prognostic significance of DNA ploidy and morphometric analyses of adenocarcinoma of the uterine cervix. Anal Quant Cytol Histol. 1987; (1): 17-24
- Rhabdomyosarcoma of the uterine cervix. Sarcoma botryoides. Cancer. 1987; (7): 1552-60
- Antitumor and immunologic effects of a pyridine-extracted fraction of Propionibacterium acnes. Cancer Immunol Immunother. 1986; (1): 24-30
- CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol. 1986; (5): 685-9
- Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol. 1986; (6): 783-8
- Human papillomavirus deoxyribonucleic acid in adenocarcinoma and adenosquamous carcinoma of the uterine cervix. Obstet Gynecol. 1986; (2): 241-4
- Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors. Obstet Gynecol. 1986; (4): 478-82
- Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study. Gynecol Oncol. 1986; (1): 101-4
- The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol. 1986; (1): 56-60
- Adenocarcinoma of the uterine cervix: histologic variables associated with lymph node metastasis and survival. Obstet Gynecol. 1985; (1): 46-52
- Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. Am J Obstet Gynecol. 1985; (8): 1003-10
- Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer. Cancer Treat Rev. 1985: 23-32
- Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Cancer Res. 1985; (9): 4447-53
- Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer. J Natl Cancer Inst. 1985; (2): 349-55
- Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model. Cancer Res. 1985; (9): 4215-8
- Whole abdominal radiation as salvage therapy for epithelial ovarian cancer. Obstet Gynecol. 1985; (1): 60-6
- Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum. J Biol Response Mod. 1984; (4): 371-8
- Immunotherapy with biochemically dissociated fractions of Propionibacterium acnes in a murine ovarian cancer model. Cancer Res. 1984; (5): 1871-5
- Individualization of treatment for stage I squamous cell vulvar carcinoma. Obstet Gynecol. 1984; (2): 155-62
- Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet Gynecol. 1984; (5): 708-14
- Preoperative radiation therapy for locally advanced vulvar cancer. Cancer. 1984; (10): 2056-61
- Rectosigmoid colectomy and reanastomosis to facilitate resection of primary and recurrent gynecologic cancer. Obstet Gynecol. 1984; (5): 715-20
- Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice. Cancer Res. 1984; (11): 5118-23
- Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status. Obstet Gynecol. 1984; (2): 207-12
- Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity. J Immunol. 1984; (1): 519-26
- Vaginal reconstruction performed simultaneously with pelvic exenteration. Obstet Gynecol. 1984; (3): 318-23
- Delayed vaginal reconstruction in the fibrotic pelvis following radiation or previous reconstruction. Obstet Gynecol. 1983; (6): 743-8
- Estrogen and progesterone receptors in ovarian neoplasms. Gynecol Oncol. 1983; (3): 299-304
- Laparoscopy in the management of patients with ovarian carcinoma. Clin Obstet Gynaecol. 1983; (2): 213-22
- Microinvasive carcinoma of the vulva. Obstet Gynecol. 1983; (1): 134-5
- Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep. 1983; (12): 1085-92
Help
Trial Administration